FDA Brief

Warning letters Drugs

FDA warning letter to

Notarika, S.A. de C.V.

High riskIssued Oct 7, 2021Posted Oct 12, 2021Center for Drug Evaluation and Research | CDER

Notarika’s Greenfrog hand sanitizer was refused at the U.S. border after FDA found methanol instead of ethanol.

What happened

FDA tested batches of Greenfrog HAND SANITIZER, a consumer antiseptic hand rub labeled as made by Notarika, after an attempted import was detained and refused admission at the U.S. border. The label said the product contained 70% ethanol, but FDA laboratory testing found an average of 0% ethanol and 54% methanol v/v. FDA also cited the product as an unapproved new drug and as misbranded (labeling violations).

What FDA found

  1. The hand sanitizer’s labeled active ingredient, ethanol, was replaced wholly or partly with methanol, a dangerous chemical.

    FD&C Act section 501(d)(2), 21 U.S.C. 351(d)(2)
  2. The substitution shows the facility’s quality assurance was not working under current good manufacturing practice (CGMP).

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The hand sanitizer is an unapproved new drug—it is marketed without FDA approval and does not meet the conditions for marketing under section 505G.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  4. The label is false or misleading because it claims 70% ethanol while testing found 0% ethanol and undeclared methanol.

    FD&C Act section 502(a), 21 U.S.C. 352(a)
  5. The label lacks a Drug Facts panel and does not separately list active and inactive ingredients.

    FD&C Act section 502(c), 21 U.S.C. 352(c); 21 CFR 201.66
  6. The label lacks the required “If swallowed...” warning, and the clear bottle resembles a drinking water bottle.

    FD&C Act sections 502(f)(2) and 502(i)(1), 21 U.S.C. 352(f)(2) and 352(i)(1)

What FDA wants

FDA tells Notarika to respond in writing within 15 working days with a detailed investigation into the methanol substitution, all raw materials and suppliers, all hand sanitizer lots and distribution reconciliation, and complete batch records for U.S.-distributed batches. FDA also recommends a qualified current good manufacturing practice (CGMP) consultant and a Regulatory Meeting if the firm wants to make drugs for the U.S. market in the future.

Who should pay attention

  • distributors and importers of Greenfrog hand sanitizer
  • brands that buy hand sanitizer from Mexican contract manufacturers
  • retailers and consumers of alcohol-based hand rubs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  2. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  3. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  4. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk